⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYMR News
Kymera Therapeutics, Inc. Common Stock
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
globenewswire.com
AZN
CRSP
NKTR
INCY
IPHA
ABBV
BIIB
ALKS
IMVT
CLRB
IMPP
REGN
THO
AUTL
KYMR
CBIO
GILD
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
globenewswire.com
IMVT
ROIV
CART
NVS
MRK
REGN
UCB
JNJ
AMGN
ARGX
KYMR
CABA
BMY
BHVN
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
globenewswire.com
KYMR
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
globenewswire.com
KYMR
GILD
Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
BIIB
NVS
VTRS
UCB
BMY
ABBV
AZN
CABA
AUR
GSK
VERA
KYMR
NKTR
VRTX
ARWR
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
globenewswire.com
KYMR
Form 8-K
sec.gov
KYMR
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
globenewswire.com
KYMR
Global Powder Metallurgy Market to Reach USD 7.68 Billion by 2032, Growing at 12% CAGR as EV Manufacturing and Sustainable Metal Processing Expand
prnewswire.com
RIO
ATI
KYMR
Form 8-K
sec.gov
KYMR